(Q37263317)

English

In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012.

scientific article published on 12 August 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

19 August 2017

In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012. (English)

1 reference

Europe PubMed Central

19 August 2017

Pseudomonas aeruginosa

0 references

author name string

A Walkty

1

1 reference

Europe PubMed Central

19 August 2017

J A Karlowsky

2

1 reference

Europe PubMed Central

19 August 2017

H Adam

3

1 reference

Europe PubMed Central

19 August 2017

M Baxter

4

1 reference

Europe PubMed Central

19 August 2017

P Lagacé-Wiens

5

1 reference

Europe PubMed Central

19 August 2017

D J Hoban

6

1 reference

Europe PubMed Central

19 August 2017

G G Zhanel

7

1 reference

Europe PubMed Central

19 August 2017

language of work or name

0 references

publication date

12 August 2013

1 reference

Europe PubMed Central

19 August 2017

number of pages

3

1 reference

based on heuristic

inferred from page(s)

Antimicrobial Agents and Chemotherapy

1 reference

Europe PubMed Central

19 August 2017

57

1 reference

Europe PubMed Central

19 August 2017

11

1 reference

Europe PubMed Central

19 August 2017

5707-5709

1 reference

Europe PubMed Central

19 August 2017

Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3811242

6 September 2017

Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: results of the Canadian Ward Surveillance Study (CANWARD 2008).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3811242

6 September 2017

Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3811242

6 September 2017

Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3811242

6 September 2017

Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3811242

6 September 2017

Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3811242

6 September 2017

In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3811242

6 September 2017

Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3811242

6 September 2017

Overview of nosocomial infections caused by gram-negative bacilli

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3811242

6 September 2017

Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3811242

6 September 2017

Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3811242

26 June 2018

Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3811242

26 June 2018

Antimicrobial susceptibility of Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals: CANWARD 2008-2011.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3811242

3 September 2018

Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: risk factors and mortality

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3811242

3 September 2018

In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3811242

3 September 2018

Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3811242

3 September 2018

Epidemiology and frequency of resistance among pathogens causing urinary tract infections in 1,510 hospitalized patients: a report from the SENTRY Antimicrobial Surveillance Program (North America).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3811242

3 September 2018

Stability of FR264205 against AmpC beta-lactamase of Pseudomonas aeruginosa

1 reference

https://pubmed.ncbi.nlm.nih.gov/23939895

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1128/AAC.01404-13

1 reference

Europe PubMed Central

19 August 2017

release_gj775vzshvekdieuo4kfyw2b64

1 reference

https://api.fatcat.wiki/v0/release/gj775vzshvekdieuo4kfyw2b64

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

19 August 2017

1 reference

Europe PubMed Central

19 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37263317&oldid=1842545823"